Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin

Sodium glucose cotransporter-2 (SGLT2) inhibitors are glucose-lowering drugs with proven efficacy in treating type 2 diabetes mellitus, and more recently, have been shown to improve heart failure outcomes in patients without diabetes. A rare complication of SGLT2 inhibitor use is the development of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ case reports 2022-06, Vol.15 (6), p.e247921
Hauptverfasser:	Bardhi, Olgert, Bloom, Matthew D, Sattari, Maryam
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen Acidosis Alcohol use Antidiabetics Benzhydryl Compounds Case reports Case Reports: Unusual association of diseases/symptoms Chloride Cocaine Diabetes Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic ketoacidosis Diabetic Ketoacidosis - chemically induced Diabetic Ketoacidosis - diagnosis Diabetic Ketoacidosis - drug therapy Diet Glucose Glucosides Hospitals Humans Hyperglycemia Insulin Liver diseases Male Metabolism Pain Pancreatitis Pancreatitis - complications Patients Risk factors Sodium Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Sodium glucose cotransporter-2 (SGLT2) inhibitors are glucose-lowering drugs with proven efficacy in treating type 2 diabetes mellitus, and more recently, have been shown to improve heart failure outcomes in patients without diabetes. A rare complication of SGLT2 inhibitor use is the development of euglycaemic diabetic ketoacidosis (EDKA), characterised by euglycaemia (blood glucose level
ISSN:	1757-790X 1757-790X
DOI:	10.1136/bcr-2021-247921